Stay updated with breaking news from Diamondtemp Ablation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
North America to account for larger share in atrial fibrillation market during 2022–2028; growth driven by rising geriatric population, increasing occurrence of cardiovascular diseases, high accessibility to advanced technologies, growing development of innovative and technologically advanced products, and increasing healthcare expenditure
/PRNewswire/ -- DelveInsight's Cardiac Ablation Devices Market Insights and Forecast report provides the current and forecast Cardiac Ablation Devices Market,...
The Shockwave intravascular lithotripsy system produces a flash of light as it releases a sonic shockwave, as seen here as it is about to shatter a gypsum bead during a TCT 2019 demonstration at the vendor's booth. You can see the cracks forming as the bead breaks apart in the right bead. The technology combines a miniaturized lithotripsy system with a low-pressure balloon catheter to expand peripheral or coronary arteries without causing vessel trauma. Photo by Dave Fornell
Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027 Financialnewsmedia.com News Commentary Palm Beach, Fl., Feb. 11, 2021 /PRNewswire/ -- Cardiovascular devices are the medical devices which are used to diagnosis and treat the heart diseases and other heart-related problems. These devices play essential role prevention and treatment of cardiovascular diseases. The cardiovascular devices include implantable cardioverter defibrillators, implanted heart rhythm monitors, pacemakers, and various other devices. The cardiovascular devices market is currently witnessing co...
email article COVID-19 has been outpacing heart disease as the top killer in the U.S. for months, but the relative rankings are likely to be affected "for years to come," the American Heart Association projected. An algorithm for the KardiaMobile 6L ECG wearable automatically detected QT prolongation with sensitivity of 80% and specificity of 94%, researchers reported in Circulation. AliveCor also announced the rollout of a wider range of arrhythmia detection for its devices that the FDA had cleared in November. Hybrid gene therapy could hold promise for long QT syndrome, according to ...